Alembic Pharmaceuticals Limited (BOM:533573)
India
· Delayed Price · Currency is INR 881.80
-7.10 (-0.80%)
At close: Apr 4, 2025
Alembic Pharmaceuticals Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2015 - 2019 |
Net Income | - | 6,158 | 3,420 | 5,209 | 11,465 | 8,288 | Upgrade
|
Depreciation & Amortization | - | 2,727 | 2,754 | 2,868 | 1,835 | 1,569 | Upgrade
|
Other Amortization | - | - | 984.4 | 801.3 | - | - | Upgrade
|
Loss (Gain) From Sale of Assets | - | -17 | 47 | -5.4 | -13.9 | -11.6 | Upgrade
|
Asset Writedown & Restructuring Costs | - | - | - | - | - | 541.4 | Upgrade
|
Loss (Gain) From Sale of Investments | - | -27.6 | -1.4 | - | -13.3 | 327.2 | Upgrade
|
Loss (Gain) on Equity Investments | - | 9.8 | 309.2 | -52.8 | - | - | Upgrade
|
Provision & Write-off of Bad Debts | - | 53.6 | - | 73 | 60.6 | 85.5 | Upgrade
|
Other Operating Activities | - | 84.8 | 301.7 | 303.6 | -1,082 | -379.9 | Upgrade
|
Change in Accounts Receivable | - | 390.5 | -2,229 | -4,696 | 5,109 | -3,583 | Upgrade
|
Change in Inventory | - | -1,683 | 1,344 | -1,236 | -2,986 | -2,203 | Upgrade
|
Change in Accounts Payable | - | 560.4 | -281.7 | 366.7 | 452.7 | -211.1 | Upgrade
|
Change in Other Net Operating Assets | - | -224.6 | 590.5 | 1,892 | -192.8 | 68 | Upgrade
|
Operating Cash Flow | - | 8,032 | 7,240 | 5,524 | 14,634 | 4,491 | Upgrade
|
Operating Cash Flow Growth | - | 10.95% | 31.07% | -62.26% | 225.82% | -44.69% | Upgrade
|
Capital Expenditures | - | -3,275 | -4,434 | -4,256 | -6,595 | -7,349 | Upgrade
|
Sale of Property, Plant & Equipment | - | 115.6 | 18.7 | 13.9 | 2.7 | 6 | Upgrade
|
Investment in Securities | - | -83.2 | -70 | 476.8 | -1,861 | - | Upgrade
|
Other Investing Activities | - | 36.2 | 9.5 | 46 | 65.3 | 26.6 | Upgrade
|
Investing Cash Flow | - | -3,206 | -4,476 | -3,720 | -8,388 | -7,316 | Upgrade
|
Short-Term Debt Issued | - | - | 2,059 | 4,300 | - | 4,314 | Upgrade
|
Long-Term Debt Issued | - | - | - | - | - | 3,780 | Upgrade
|
Total Debt Issued | - | - | 2,059 | 4,300 | - | 8,094 | Upgrade
|
Short-Term Debt Repaid | - | -2,054 | - | - | -8,605 | - | Upgrade
|
Long-Term Debt Repaid | - | -258.2 | -2,231 | -3,202 | -3,980 | -2,175 | Upgrade
|
Total Debt Repaid | - | -2,312 | -2,231 | -3,202 | -12,585 | -2,175 | Upgrade
|
Net Debt Issued (Repaid) | - | -2,312 | -172.3 | 1,098 | -12,585 | 5,919 | Upgrade
|
Issuance of Common Stock | - | - | - | - | 7,341 | - | Upgrade
|
Common Dividends Paid | - | -1,573 | -1,966 | -2,752 | - | -2,356 | Upgrade
|
Other Financing Activities | - | -493.9 | -481.7 | -519.7 | -730.4 | -1,449 | Upgrade
|
Financing Cash Flow | - | -4,379 | -2,620 | -2,174 | -5,974 | 1,549 | Upgrade
|
Foreign Exchange Rate Adjustments | - | - | - | - | -9.3 | 4.1 | Upgrade
|
Miscellaneous Cash Flow Adjustments | - | 0.1 | -0.1 | - | 0.1 | 0.1 | Upgrade
|
Net Cash Flow | - | 447.3 | 143.9 | -369.7 | 262.2 | -1,272 | Upgrade
|
Free Cash Flow | - | 4,757 | 2,805 | 1,267 | 8,039 | -2,858 | Upgrade
|
Free Cash Flow Growth | - | 69.58% | 121.40% | -84.24% | - | - | Upgrade
|
Free Cash Flow Margin | - | 7.64% | 4.96% | 2.39% | 14.90% | -6.20% | Upgrade
|
Free Cash Flow Per Share | - | 24.20 | 14.27 | 6.45 | 41.49 | -15.16 | Upgrade
|
Cash Interest Paid | - | 493.7 | 497 | 519.2 | 729.4 | 1,111 | Upgrade
|
Cash Income Tax Paid | - | 198.5 | 607 | 1,234 | 2,454 | 2,699 | Upgrade
|
Levered Free Cash Flow | - | 2,198 | 504.46 | -324.73 | 4,359 | -5,119 | Upgrade
|
Unlevered Free Cash Flow | - | 2,549 | 818.03 | -213.91 | 4,459 | -4,949 | Upgrade
|
Change in Net Working Capital | - | 1,032 | 1,223 | 3,298 | -1,114 | 6,116 | Upgrade
|
Updated Feb 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.